Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2.

2.

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5. Erratum in: Oncotarget. 2019 Apr 2;10(26):2576.

3.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.

J Neurooncol. 2017 Nov;135(2):273-284. doi: 10.1007/s11060-017-2570-1. Epub 2017 Sep 7.

PMID:
28884377
4.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.

5.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.

Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R; Spanish Lung Cancer Group.

Clin Lung Cancer. 2017 Mar;18(2):178-188.e4. doi: 10.1016/j.cllc.2016.08.007. Epub 2016 Nov 9.

PMID:
27908619
6.

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.

Romeo M, Karachaliou N, Chaid I, Queralt C, De Aguirre I, Del Carmen Gómez M, Sanchez-Ronco M, Radua J, Ramírez JL, Rosell R.

Int J Biol Markers. 2017 Mar 2;32(1):e90-e95. doi: 10.5301/jbm.5000223.

PMID:
27443420
7.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group.

JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.

PMID:
26181014
8.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
9.

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M.

PLoS One. 2014 Feb 25;9(2):e89518. doi: 10.1371/journal.pone.0089518. eCollection 2014.

10.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
11.

Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes.

Enjuanes A, Benavente Y, Hernández-Rodríguez J, Queralt C, Yagüe J, Jares P, de Sanjosé S, Campo E, Cid MC.

Rheumatology (Oxford). 2012 May;51(5):841-51. doi: 10.1093/rheumatology/ker429. Epub 2012 Jan 17.

PMID:
22258388
12.

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M.

Clin Cancer Res. 2011 Mar 1;17(5):1160-8. doi: 10.1158/1078-0432.CCR-10-2158. Epub 2011 Jan 13.

13.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.

Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R, Massuti B, Benlloch S, Ramon y Cajal S, Taron M, Rosell R.

J Transl Med. 2010 Dec 18;8:135. doi: 10.1186/1479-5876-8-135.

14.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R.

Eur Respir J. 2011 Mar;37(3):624-31. doi: 10.1183/09031936.00195609. Epub 2010 Jul 1.

15.

Biomarkers in lung oncology.

Rosell R, Vergnenegre A, Liu B, Cobo M, Massuti B, Wei J, Molina MA, Costa C, Queralt C, Taron M.

Pulm Pharmacol Ther. 2010 Dec;23(6):508-14. doi: 10.1016/j.pupt.2010.05.003. Epub 2010 May 13. Review.

PMID:
20471486
16.

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group.

N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.

17.

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations.

Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjós M, Castellà E, Moran T, Bertran-Alamillo J, Mayo-de-Las-Casas C, Queralt C, Rosell R.

Eur Respir J. 2010 Feb;35(2):391-5. doi: 10.1183/09031936.00028109. Epub 2009 Jul 30.

18.

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.

Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castellà E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomàs M, Mate JL, Moran T, Rosell R.

J Thorac Oncol. 2008 Nov;3(11):1224-35. doi: 10.1097/JTO.0b013e318189f579.

19.

Triage flowchart to rule out acute coronary syndrome.

Sánchez M, López B, Bragulat E, Gómez-Angelats E, Jiménez S, Ortega M, Coll-Vinent B, Alonso JR, Queralt C, Miró O.

Am J Emerg Med. 2007 Oct;25(8):865-72.

PMID:
17920969
20.

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R; Spanish Lung Cancer Group.

Ann Oncol. 2006 Apr;17(4):668-75. Epub 2006 Jan 11.

PMID:
16407418
21.

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T.

Clin Cancer Res. 2005 Aug 15;11(16):5878-85.

22.

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.

Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama K, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ.

Lung Cancer. 2005 Oct;50(1):25-33.

PMID:
16011858
23.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M.

Ann Oncol. 2005 Jul;16(7):1081-6. Epub 2005 Apr 25.

PMID:
15851406
24.

Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.

Felip E, Taron M, Rosell R, Mendez P, Queralt C, Ronco MS, Sanchez JJ, Sanchez JM, Maestre J, Majo J.

Clin Lung Cancer. 2005 Mar;6(5):299-303.

PMID:
15845181
25.

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J.

Hum Mol Genet. 2004 Oct 15;13(20):2443-9. Epub 2004 Aug 18.

PMID:
15317748
26.

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.

Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4215s-4219s.

27.

Serum DNA as a tool for cancer patient management.

Ramirez JL, Taron M, Balaña C, Sarries C, Mendez P, de Aguirre I, Nuñez L, Roig B, Queralt C, Botia M, Rosell R.

Rocz Akad Med Bialymst. 2003;48:34-41.

PMID:
14737938
28.

Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC.

Rheumatology (Oxford). 2004 Mar;43(3):294-301. Epub 2003 Dec 16.

PMID:
14679293
29.

Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients.

Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, Sancho E, Martinez N, Tarón M, Rosell R.

Clin Lung Cancer. 2003 Jan;4(4):237-41.

PMID:
14624713
30.

[Survey of emergency departments preparedness for terrorist attacks with weapons of mass destruction].

Miró O, Trejo O, Queralt C, Sánchez M.

Med Clin (Barc). 2003 Nov 1;121(15):596-7. Spanish. No abstract available.

PMID:
14622529
31.

[Emergency department overcrowding: quantification of associated factors].

Sánchez M, Miró O, Coll-Vinent B, Bragulat E, Espinosa G, Gómez-Angelats E, Jiménez S, Queralt C, Hernández-Rodríguez J, Alonso JR, Millá J.

Med Clin (Barc). 2003 Jul 5;121(5):161-72. Spanish.

PMID:
12867001
32.

Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.

Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margelí M, Sanchez JJ, Astudillo J, Taron M, Rosell R.

Cancer Lett. 2003 Apr 25;193(2):207-16.

PMID:
12706879
33.

Beta-tubulin mutational analysis: tantalizing findings.

Rosell R, Tarón M, Sarries C, Queralt C, Roig B.

Lung Cancer. 2002 Oct;38(1):99-100. No abstract available.

PMID:
12367801
34.

[Right pleural effusion as an isolated manifestation of ovarian hyperstimulation syndrome].

Laguno M, Queralt C, Casademont J.

Med Clin (Barc). 2000 Oct 7;115(11):438. Spanish. No abstract available.

PMID:
11093850
35.
36.

[Detection of bacteremia in patients discharged from an emergency unit: study of 61 cases].

Tudela P, Queralt C, Giménez M, Carreres A, Tor J, Sopena N, Valencia J.

Med Clin (Barc). 1998 Sep 5;111(6):201-4. Spanish.

PMID:
9789224
37.

Osteonecrosis and HIV infection: 4 more cases.

Olivé A, Queralt C, Sirera G, Centelles M, Force L.

J Rheumatol. 1998 Jun;25(6):1243-4. No abstract available.

PMID:
9632097
38.

[Bacteremia detected among patients discharged from the emergency service].

Tudela P, Queralt C, Giménez M, Carreres A.

Med Clin (Barc). 1996 Oct 19;107(13):519. Spanish. No abstract available.

PMID:
9045024
39.

Local anesthesia by jet-injection device in minor dermatologic surgery.

Queralt CB, Comet V Jr, Cruz JM, Val-Carreres C.

Dermatol Surg. 1995 Jul;21(7):649-51.

PMID:
7606381
40.

[Obstructive jaundice due to peripancreatic tuberculous adenitis].

Queralt CB, Cruz JM, Comet V Jr, Almajano C, Val-Carreres C.

Rev Esp Enferm Dig. 1992 Sep;82(3):201-2. Spanish. No abstract available.

PMID:
1419321
41.

[Changes in nutritional and biochemical parameters in septic patients undergoing total parenteral nutrition. Their relationship with mortality].

Celaya S, Laguens G, Elósegui LM, Queralt C, Sagredo A, Jiménez A, Civeira E.

Nutr Hosp. 1990 Sep-Oct;5(5):311-6. Spanish.

PMID:
2127722
42.

[Experimental model of acute peritonitis. Microbiological findings and mortality].

Queralt CB, Egido P, Morandeira JR, Laguens G, Castillo J, Lozano R.

Rev Esp Enferm Apar Dig. 1987 Nov;72(5 Pt 2):595-7. Spanish. No abstract available.

PMID:
3448693

Supplemental Content

Loading ...
Support Center